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Abstract
Background Pipamperone is a frequently prescribed antipsychotic in children and adolescents in the Netherlands, Belgium, 
and Germany. However, pediatric pharmacokinetics and the relationship with side effects and efficacy are unknown. Cur-
rently, divergent pediatric dosing recommendations exist.
Objectives The objective of this study was to describe the population pharmacokinetics of pipamperone in children and 
adolescents; to correlate measured and predicted pipamperone trough concentrations and predicted 24-h area under the curves 
with effectiveness, extrapyramidal symptoms, and sedation; and to propose dose recommendations based on simulations.
Methods Pipamperone concentrations were collected from Dutch pediatric patients in a prospective naturalistic trial (n = 8), 
and German pediatric patients in a therapeutic drug monitoring service (n = 22). A total of 70 pipamperone concentrations 
were used to develop a population pharmacokinetic model with non-linear mixed-effects modeling  (NONMEM®). Addition-
ally, an additional random sample of 21 German patients with 33 pipamperone concentrations from the same therapeutic 
drug monitoring service was used for external validation. Pharmacokinetic parameters were related to clinical improvement, 
sedation, and extrapyramidal symptoms. Simulations were performed to determine optimal dosages.
Results In a one-compartment model, the apparent volume of distribution was 416 L/70 kg and the apparent clearance was 
22.1 L/h/70 kg. Allometric scaling was used to correct for differences in bodyweight. The model was successfully externally 
validated. The median [25th–75th percentile] measured pipamperone trough concentrations were numerically higher in 
responders (98.0 µg/L [56.0–180.5 µg/L]) than in non-responders (58.0 µg/L [14.9–105.5 µg/L]), although non-significant 
(p = 0.14). A twice-daily 0.6-mg/kg dosage was better than a fixed dosage to attain the concentration range observed in 
responders.
Conclusions Our findings suggest that pipamperone therapeutic reference ranges may be lower for children with behavioral 
problems than recommended for adults with psychotic symptoms (100–400 µg/L). When dosing pipamperone in children 
and adolescents, bodyweight should be taken into account.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 2-020-00894 -y) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Pipamperone is one of the most frequently prescribed antip-
sychotics for children and adolescents in the Netherlands, 
Germany, and Belgium [1–3]. Between 2005 and 2015, 18% 
of all antipsychotics prescribed to children and adolescents 
in the Netherlands concerned pipamperone, with similar but 
slightly lower prescription rates in Germany and Belgium 
[1–3]. These prescription rates have been fairly constant for 
the past decades.
Pipamperone, being introduced in 1961 as  Dipiperon® by 
Janssen Pharmaceutica, is considered a low-potency antipsy-
chotic owing to the relatively low affinity for the  D2 recep-
tor. The antagonism of the serotonin 5-HT2 and adrenergic 
 alpha1 receptor is more pronounced [4], which explains its 
sedative effect, which is partly the result of relative hypop-
erfusion in the brain [5, 6]. For this reason, pipamperone 
has not only been explored for its antipsychotic properties 
[7], but also as a hypnotic in patients with sleep disorders, 
showing good efficacy [8].
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Key Points 
Pipamperone pharmacokinetic parameters in children 
and adolescents are comparable to adult values from the 
literature.
Children and adolescents with responses during pipam-
perone treatment have higher pipamperone trough 
concentrations and 24-h area under the curves than non-
responders.
Bodyweight-adjusted pipamperone dosages are better 
than fixed dosages to attain the concentrations observed 
in responders. A twice-daily dosing scheme is recom-
mended based on a relatively long elimination half-life 
(13 h).
While data on the efficacy and side effects are scarce, 
publicly available pharmacokinetic data of pipamperone in 
children and adolescents are completely missing. In adults, 
some pharmacokinetic studies have been performed, show-
ing a maximum plasma concentration after 1–2 h and an 
elimination half-life of 12–30 h [4, 21, 22]. However, in 
children and adolescents, both pharmacokinetics and phar-
macodynamics are expected to be considerably different, as 
some consensus based-dosing guidelines advise lowering 
the starting dose in this population by 95% compared to 
recommended doses in adults, resulting in 2 mg instead of 
40 mg [16].
The aim of this study was to describe the population 
pharmacokinetics of pipamperone in children and adoles-
cents. Furthermore, the relationships of the pharmacokinetic 
parameters of pipamperone with both clinical improvement 
and side effects, including sedation and EPS in children and 
adolescents, were explored. These data will provide a more 
solid basis for pipamperone dose recommendations in this 
vulnerable patient population.
2  Methods
2.1  Study Population
The study population consisted of two samples. The first 
sample included children and adolescents who were pro-
spectively enrolled in a Dutch multicenter observational trial 
(SPACe, NTR6050). Inclusion criteria were: age 6–18 years, 
documented clinical diagnosis of autism spectrum dis-
order according to the Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition [23] or Fifth Edition 
[24] and comorbid behavioral problems, and treatment with 
pipamperone. Exclusion criteria were: type 1 or 2 diabetes 
mellitus, congenital or acquired syndrome associated with 
changes in appetite, body weight or lipid profile (e.g., Prader 
Willi), treatment with another antipsychotic within the last 
6 months, or known Long QT syndrome. Eligible patients 
were treated in an inpatient or outpatient setting in one of the 
seven participating centers in the south-west region of the 
Netherlands (two academic tertiary care centers and five psy-
chiatric secondary care centers). Subjects were prescribed 
flexible pipamperone dosages once or twice daily, as part 
of routine clinical care by the treating physician. Pipamper-
one was prescribed as a tablet formulation or oral solution. 
Patients were recruited between August 2016 and May 2018. 
All patients and/or their legal representatives gave written 
informed consent before entering the study. The study was 
approved by the Medical Ethics Committee of the Erasmus 
Medical Centre, the Netherlands (number MEC 2016-124).
The second sample consisted of children and adolescents 
of whom pipamperone concentrations had been measured as 
However, in children and adolescents, pipamperone is 
particularly prescribed for behavioral problems, like other 
antipsychotics in this population [2, 9, 10]. Severe behav-
ioral problems in youths represent the main symptoms of 
conduct disorder, or may occur within other psychiatric dis-
orders such as autism spectrum disorder, attention-deficit/
hyperactivity disorder, or mental retardation. Pipamper-
one may be a preferred antipsychotic for these indications, 
mainly because of the calming effects and the availability 
of an oral liquid formulation, enabling flexible dosing [11, 
12]. However, despite the extensive practical experience in 
children and adolescents, the evidence for the efficacy of 
pipamperone is very limited. Although two small open-label 
studies from the 1970s showed positive results for the treat-
ment of behavioral problems in children and adolescents, 
randomized controlled trials are lacking [13, 14]. For this 
reason, prescribing pipamperone to youths is currently con-
sidered off-label or restricted to use with particular consid-
eration of the benefit-risk ratio, depending on the country 
[15, 16]. Indications for use as mentioned in the summary 
of product characteristics within the Netherlands, Germany, 
and Belgium include psychomotor agitation and behavioral 
problems, with depression of the central nervous system 
being a major clinical contra-indication [4, 15, 17].
Side effects of pipamperone mainly concern sedation and 
extrapyramidal symptoms (EPS) [4, 18]. Prolactin elevation 
has also been reported, and is associated with galactorrhea 
and amenorrhea [4]. Although weight gain and metabolic 
changes have become the major concern for atypical antipsy-
chotic use in children and adolescents [19], these side effects 
have not been described in the literature for pipamperone. 
However, as antipsychotic-induced weight gain is believed to 
be partly attributed to the serotonin system [20], the 5-HT2 
antagonism of pipamperone is likely to induce weight gain 
as well.
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part of the routine therapeutic drug monitoring (TDM) ser-
vice of the Department of Child and Adolescent Psychiatry, 
Psychosomatics and Psychotherapy at the University Hos-
pital of Wuerzburg, Germany. Subjects were treated at this 
clinic or at associated clinics for child and adolescent psy-
chiatry within the competence network of TDM in child and 
adolescent psychiatry, which is described elsewhere [25]. 
Patients were prescribed flexible dosages of pipamperone 
as a tablet or oral solution, being administered once up to 
five times daily. The pipamperone samples were collected 
between June 2008 and February 2015 in patients with vari-
ous psychiatric diagnoses. The Medical Ethics Committee 
of the University of Wuerzburg approved the study (study 
number 27/04) and waived informed consent, as drug con-
centrations were measured as part of routine care. Both stud-
ies were conducted in accordance with the Declaration of 
Helsinki.
2.2  Pipamperone Concentrations
In the Dutch trial, a total of six pipamperone drug concentra-
tions per subject were collected at random time points on two 
separate days during a 6-month follow-up with 3–6 months 
in between sampling. The time between two samples was at 
least 1 h. Samples were collected with venipuncture and the 
dried blood spot (DBS) method. The time of sampling, time 
of last pipamperone intake, the pipamperone dosages, and 
comedication during follow-up were recorded. Both sam-
ples in steady state and non-steady state were collected. The 
Dutch samples were analyzed using previously validated, 
ultra-high performance liquid chromatography-mass spec-
trometry methods for plasma and DBS [26–28]. The lower 
limit of quantification (LLOQ) was 1.5 µg/L. The accuracy 
of the quality-control samples was well below a limit of rela-
tive standard deviation of 15% and the intra- and inter-assay 
imprecision was less than 15% during the study period.
Within the German TDM service, samples were collected 
with venipuncture in the morning before the first pipamper-
one dosage of that day (trough concentrations) [21]. The 
pipamperone dosage and administration time (morning, 
midday, evening) were reported on the request form. Only 
concentrations measured in steady state were included for 
analyses, as for non-steady state samples previous dosages 
were not known. The German samples were analyzed with 
a validated serum high-performance liquid chromatography-
ultraviolet (HPLC–UV) method for plasma. The LLOQ was 
8 µg/L. The method was linear in a range of 2–1050 µg/L 
(r2 = 0.99952). Concentrations below the LLOQ were 
excluded, as for these no quantification of the plasma con-
centration was provided.
2.3  Assessment of Clinical Outcomes
In the Dutch trial, measures of clinical effectiveness and 
side effects were collected at baseline and prospectively 
during the 6-month follow-up (at 6 months and for a subset 
of patients at 1 and 3 months). Clinical effectiveness was 
measured by the Clinical Global Impression (CGI) Scale 
[29]. This scale describes the severity of psychopathology 
(CGI-S) and its improvement (CGI-I) by seven categories, 
rated by the treating physician. The CGI-S describes the 
severity of illness relative to the physicians’ experience 
with patients with the same diagnosis: 0 = not assessable; 
1 = normal; 2 = borderline; 3 = mildly ill; 4 = moderately 
ill; 5 = markedly ill; 6 = severely ill; 7 = extremely ill. The 
CGI-I rates the improvement in comparison to the origi-
nal medication-naive state of symptoms: 0 = not assessable, 
1 = very much better, 2 = much better, 3 = moderately bet-
ter, 4 = unchanged, 5 = minimally worse, 6 = much worse. 
Extrapyramidal symptoms were measured with the Abnor-
mal Involuntary Movement Scale (AIMS) (completed by the 
treating physician or researcher) [29] and sleepiness with 
the Epworth Sleepiness Scale (completed by parents) [30]. 
Biochemical laboratory check-ups were performed at base-
line, after 6 months, and for a subset of children at 3 months, 
and included renal function, liver function, fasting glucose, 
glycosylated hemoglobin, prolactin, cholesterol, fatty acids, 
and albumin. During follow-up, medication adherence was 
measured with questionnaires (Medication Adherence Rat-
ing Scale, MARS-5 [31], completed by parents, and a visual 
analog scale, completed by parents and treating physician) 
and during the last month of follow-up with an electronic 
monitoring system  (MEMS©) [32]. Weight and height were 
measured at baseline, at the time of blood sampling and, for 
a subset of children, after 1 month of follow-up.
At the German TDM service, the following information 
was recorded on the request form at the time of sampling: 
renal dysfunction, hepatic dysfunction, smoking status, cur-
rent infection, comedication, CGI-S, CGI-I, and side effects 
with the Udvalg for Kliniske Undersøgelser Side Effect Rat-
ing Scale [33]. The Udvalg for Kliniske Undersøgelser Side 
Effect Rating Scale rates the severity of side effects with the 
following categories: 0 = no side effects; 1 = mild, 2 = mod-
erate, and 3 = severe. The nature of the side effects was also 
recorded and classified as follows: sedation, dermatologi-
cal, tension, salivation (more/less), accommodation disorder, 
polydipsia, delirium, EPS, cardiovascular, gastrointestinal, 
urogenital, other.
2.4  Population Pharmacokinetic Modeling
Pharmacokinetic analysis was performed by non-linear 
mixed-effects modeling using  NONMEM® Version 7.4.2 
(FOCE + I; ICON Development Solutions, Ellicott City, 
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MD, USA) and  PsN® Version 4.7.0.  Pirana® software ver-
sion 2.9.7 was used as an interface between  NONMEM® 
and R (version 3.4.4).
2.4.1  Base Model Development
One- and two-compartment models were considered with 
first-order absorption with and without lag time. Typical val-
ues for volume of distribution and clearance were estimated 
as ratios, as bioavailability could not be quantified (appar-
ent volume of distribution and apparent clearance). As the 
absorption rate constant could not be estimated, it was fixed 
at 2/h, based on the previous literature [21]. For each phar-
macokinetic parameter, inter-patient variability (IPV) was 
evaluated and shrinkage was calculated for all parameters for 
which IPV was established. A shrinkage value below 25% 
was considered acceptable [34]. Allometric scaling was used 
to account for the influence of bodyweight on pharmacoki-
netic parameters, which was explored with a fixed exponent 
of 0.75 for apparent clearance and 1 for apparent volume of 
distribution, and with exponents estimated by the model. 
Residual variability was modeled as a separated additive and 
proportional error for the analytical method (liquid chroma-
tography-mass spectrometry vs HPLC–UV) and sampling 
method (DBS vs venepuncture). Model selection was based 
on minimum objective function values, parameter precision, 
error estimates, shrinkage values, and visual inspection of 
the goodness-of-fit plots.
2.4.2  Covariate Model Development
The following covariates were considered as potential model 
covariates: sex, age, body mass index, weight, comedica-
tion, psychiatric disorder, somatic comorbidities, smoking, 
renal function, liver function, pipamperone dose, and dose/
kg. For the Dutch patients, albumin, hematocrit, and medi-
cation adherence were also known and evaluated as covari-
ates. The correlation between the covariates and IPV was 
first evaluated graphically. Subsequently, covariates with 
a visual relationship with IPV were individually added to 
the model. Continual covariates were described using an 
exponential function and categorical covariates using a pro-
portional function. The forward inclusion-backward elimi-
nation method was used [35]. Covariates that significantly 
improved the model with the univariate analysis (p < 0.05) 
were selected for the multivariate analysis. During the 
backward elimination process, covariates that improved the 
model at a level of p < 0.001 were selected.
2.4.3  Internal Model Evaluation
Two methods were used for the internal validation of the 
model. First, a bootstrap analysis was performed [36]. One 
thousand bootstrap datasets were randomly resampled from 
the original dataset with replacement. The validity of the 
model was evaluated by comparing the bootstrap estimates 
and their 95% confidence intervals with the values generated 
by the original dataset. Second, the model was evaluated 
with the visual predictive check, using a set of 1000 simu-
lated datasets to compare the observed concentrations with 
the distribution of the simulated concentrations [37].
2.4.4  External Model Evaluation
An additional dataset of another group of German patients 
from the same TDM service was used for external validation 
of the final model. Goodness-of-fit plots and a normalized 
prediction distribution error analysis (n = 1000) were used 
to evaluate the external validity [38].
2.5  Pharmacodynamic Analyses
The medians with 25th–75th percentiles of measured trough 
concentrations were correlated with CGI-I, EPS, and seda-
tion. As trough pipamperone concentrations were not avail-
able for all Dutch patients, individual trough concentrations 
were also predicted for all patients, next to 24-h area under 
the concentration–time curves (AUC 24h). These pharma-
cokinetic parameters were also correlated to CGI-I, EPS, 
and sedation. A subject was considered a responder when 
the CGI-I was rated “very much better”, “much better”, or 
“moderately better”, and a non-responder when another 
score was given (except from “not assessable”). Extrapyram-
idal symptoms were scored positive when at least two times 
“mild” or one time “moderate” in the first seven items had 
been filled in on the AIMS (Dutch patients), or when “EPS” 
was filled in as a side effect on the application form (Ger-
man patients). Sedation was considered as a score ≥ 1 on the 
Epworth Sleepiness Scale (Dutch patients) or as “sedation” 
being filled in as side effect on the application form (German 
patients). The pipamperone trough concentration, predicted 
trough concentration, and predicted AUC 24h at the time of 
the first response or side effect (EPS and sedation) was used 
for the analyses. In this analysis, efficacy was accepted as an 
endpoint regardless of the time interval since the initiation 
of treatment (but within the study period). If no response or 
side effect was observed, the highest concentration during 
the follow-up was used. Laboratory findings were compared 
with age- (and if applicable sex-) specific reference values 
as used in the Erasmus MC, University Medical Center Rot-
terdam in July 2019 [39]. The Mann–Whitney U test was 
used to compare trough concentrations and AUC 24h between 
groups. The Fisher’s Exact test was used to compare propor-
tions. A p value < 0.05 was considered significant. Graphpad 
Prism 5 (GraphPad Software, La Jolla, CA, USA) was used 
for the analyses.
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2.6  Predictions
Pipamperone concentrations using a twice-daily 30-mg 
dosing regimen were predicted for a patient of 25, 50, and 
75 kg during a 12-h time interval. After graphical inspec-
tion, a mg/kg dosage was chosen for optimal attainment of 
the concentration range associated with response based on 
pharmacodynamic analyses. This mg/kg dosage was evalu-
ated with additional predictions for a patient of 25, 50, and 
75 kg. The population predictions were used as means with 
a 95% confidence interval based on 1000 simulations of indi-
vidual predictions.
3  Results
Thirty patients with 70 measured pipamperone concentra-
tions were included in the model building group (Dutch 
patients n = 8 and German patients n = 22). Two German 
samples were below the LLOQ and were not included. The 
pipamperone concentrations were collected in the entire 
absorption and elimination phase, as can be seen in Fig. 1. 
Subsequently, 21 extra patients with 33 measured pipamper-
one concentrations were included in the external validation 
group (German patients). The baseline characteristics of the 
included patients are presented in Table 1. Most patients 
were diagnosed with autism spectrum disorder, attention 
deficit/hyperactivity disorder, or mental retardation. The 
median (range) measured pipamperone concentration was 
66.5 µg/L (0.21–1068 µg/L) in the model building group 
and 88 µg/L (16–337 µg/L) in the model validation group.
In the model building group, the n = 1 sample was below 
the LLOQ (Dutch sample). In the model validation group, 
no samples below the LLOQ were included.
Indications for a pipamperone concentration measure-
ment in the German TDM service were known for n = 60 
samples (90.9% of total n = 66 German samples). Most 
pipamperone concentrations were measured because of 
non-effectiveness (n = 16, 26.7%) or dosage change (n = 16, 
26.7%). Other indications included drug–drug interaction 
(n = 13, 21.7%), start of therapy (n = 10, 16.7%) adherence 
(n = 8, 13.3%), or side effects (n = 5, 8.3%); more than one 
reason could apply.
3.1  Pharmacokinetic Analyses
3.1.1  Base Model
The data were best described using a one-compartment 
model. This model was further improved by including an 
IPV on clearance. The residual error was described by a 
combined error model with an extra additional error for 
HPLC–UV concentrations. As the conversion of DBS 
concentrations to plasma concentrations based on the pre-
viously conducted clinical validation study [28] showed a 
trend towards under-estimation of the predicted concentra-
tions by the model, a model-based conversion was calculated 
that showed better predictions. The goodness-of-fit plots of 
the final model are presented in Fig. 2, and the parameter 
estimates of the final model are presented in Table 2.
3.1.2  Covariate Analysis
After graphical analysis, the univariate analysis resulted in 
three significant covariates for the IIV on clearance (body-
weight, creatinine, body mass index). These covariates were 
added to the base model for multivariate analysis. No covari-
ates remained significant after backward elimination except 
for bodyweight, which was best described using fixed expo-
nents with allometric scaling.
3.1.3  Evaluation of the Final Model
The model-based parameter estimates were similar to the 
values computed from the bootstrap analysis, indicating the 
stability of the model (see Table 2). The extra additional 
error for HPLC–UV concentrations was 26.6 (μg/L). The 
visual predictive check showed a good predictive perfor-
mance (figure not shown).
The model was successfully externally validated, as is 
shown by the goodness-of-fit plots and normalized predic-
tion distribution error analysis. The goodness-of-fit-plots 
show that the model adequately describes the observed 
concentrations (Fig. S1 of the Electronic Supplementary 
Material [ESM]), and the normalized prediction distribution 
error analysis shows a normal distribution of the normalized 
Fig. 1  Measured pipamperone concentrations used for model devel-
opment vs time after dose. Pipamperone concentrations were col-
lected during the absorption and elimination phase. The presented 
dried blood spot (DBS) concentrations are measured concentrations 
before conversion to estimated plasma concentrations. Four sam-
ples are not shown for readability of the figure (x = 182, y = 0.21; 
x = 118.63, y = 2.69; x = 121.4, y = 4.82; x = 12.25, y = 1068). HPLC–
UV high-performance liquid chromatography-ultraviolet, LCMS liq-
uid chromatography-mass spectrometry
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errors and some overestimation of variability (Fig. S2 of 
the ESM).
3.2  Pharmacodynamic Analyses
3.2.1  Effectiveness
For a total of 35 patients, CGI improvement scores were 
reported; 28 (80%) of them were rated as responders, and 
seven as non-responders (20%). Psychotropic comedication 
was common in both responders (68%) and non-responders 
(57%), but non-significantly different (p = 0.67).
For 29 of these patients, both CGI improvement scores 
and measured pipamperone trough concentrations were 
available. The median [25th–75th percentile] pipamperone 
trough concentration was higher in responders (98.0 µg/L 
[56.0–180.5], n = 24) than in non-responders (58.0 µg/L 
Table 1  Patient characteristics
Patient characteristics at the time of the first pipamperone concentration measurement. Presented as median 
and range for continuous variables
The model building group consisted of patients from a Dutch multicenter observational trial and patients 
from a German TDM service. The model validation group consisted of patients from the same German 
TDM service. Clinical Global Impression Scale was missing for n = 2 in the model building group and 
n = 2 in the model validation group [1 = normal; 2 = borderline; 3 = mildly ill; 4 = moderately ill; 5 = mark-
edly ill; 6 = severely ill; 7 = extremely ill]
ADHD attention deficit/hyperactivity disorder, DBS dried blood spot, TDM therapeutic drug monitoring
a Includes methylphenidate, amphetamine, and atomoxetine
b Unknown for n = 1 patient in the model building group
c Includes DBS concentrations before conversion to estimated plasma concentrations
Model building group (n = 30) Model validation group (n = 21)
Male (n) 21 (70%) 13 (61.9%)
Age (years) 13.0 (5.6–17.7) 14.9 (7.2–20.6)
Body weight (kg) 50.4 (24.8–100.4) 47.4 (24.0–118.0)
Height (cm) 152 (123–180) 155 (122–186)
Body mass index (kg/m2) 20.41 (14.3–37.2) 19.0 (12.2–43.3)
Body mass index Z score 0.98 (− 2.57 to 3.49) 0.38 (− 4.49 to 4.25)
Daily dosage (mg) 45 (12–400) 60 (10–180)
Psychiatric comedication
 Antipsychotic drugs 18 (60%) 8 (38.1%)
 ADHD  drugsa 6 (20%) 8 (38.1%)
 Tricyclic antidepressant drugs 1 (3.3%) 2 (9.5%)
 Selective serotonin re-uptake inhibitors 0 (0%) 3 (14.3%)
 Benzodiazepine agonists 1 (3.3%) 2 (9.5%)
 Lithium 1 (3.3%) 0 (0%)
Other comedication
 Antiepileptic drugs 4 (13.3%) 5 (23.8%)
Diagnosis
 Autism spectrum disorder 22 (73.3%) 4 (19.0%)
 ADHD 12 (40%) 5 (23.8%)
 Schizophrenia spectrum and other 
psychotic disorders
2 (6.7%) 0 (0%)
 Conduct disorder 1 (3.3%) 0 (0%)
 Mental retardation 9 (30%) 4 (19%)
Settingb
 Clinical 22 (73.3%) 19 (90.5%)
 Outpatient 7 (23.3%) 2 (9.5%)
No. of pipamperone samples per patient
 Pipamperone concentration (µg/L)c 1.5 (1–6) 1 (1–6)
Clinical Global Impression Scale score 5 (4–7) 5 (4–7)
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[14.91–105.5], n = 5), but this difference was non-significant 
(p = 0.14) (see Fig. 3a).
For the total sample of patients with a CGI improvement 
score (n = 35), pipamperone trough concentrations were also 
predicted based on the pharmacokinetic model. The median 
[25th–75th percentile] predicted trough concentration for 
responders was higher than in non-responders: 80.0 µg/L 
[63.0–136.6] vs 51.3 µg/L [43.4–78.8], with a trend towards 
significance (p = 0.07) (see Fig. 3b). The predicted median 
AUC 24h in responders (3448.0 µg*h/L) was also higher than 
in non-responders (1811.0 µg*h/L), p = 0.05.
When patients with ADHD and concurrent ADHD come-
dication (methylphenidate, amphetamine, or atomoxetine) 
were excluded from the analyses, the results remained the 
same. The median [25th–75th percentile] pipamperone 
trough concentration was higher in responders (113.5 µg/L 
[62.0–180.5], n = 20) than in non-responders (58.0 µg/L 
[14.91–105.5], n = 5), p = 0.10, as was the predicted trough 
concentration (83.5 µg/L [66.5–136.6], n = 24, vs 51.3 µg/L 
[43.4–78.8], n = 7), p < 0.05, and the AUC 24h (3486 µg*h/L 
vs 1811 µg*h/L), p < 0.05.
a b
c d
Fig. 2  Goodness-of-fit plots, final model. a Measured concentrations 
vs population predictions. One outlier is not presented for readability 
of the figure (x = 529.7, y = 1068). b Measured concentrations vs indi-
vidual predictions. One outlier is not presented for readability of the 
figure (x = 755.3, y = 1068). c The correlation of conditional weighted 
residuals (CWRES) with time. One outlier is not shown for readabil-
ity of the figure (time 38,232.00, CWRES 0.244350). d The correla-
tion of CWRES with population-predicted concentrations. DBS dried 
blood spot, HPLC–UV high-performance liquid chromatography-
ultraviolet, LCMS liquid chromatography-mass spectrometry
Table 2  Parameter estimates final model
CL clearance, DBS dried blood spot, HPLC–UV high-performance 
liquid chromatography-ultraviolet, IPV inter-patient variability, Ka 
absorption rate constant, RSE relative standard error, V volume of dis-
tribution
a Fixed
b Allometric scaling with exponent 1 for V and 0.75 for CL
c 90th percentile based on bootstrap with n = 772 successful runs
Parameter Estimate (RSE 
%) [shrinkage]
Bootstrap median 
(90th percentile)
Kaa (L/h) 2 2
V/Fb (L/70 kg) 416 (32) 481 (279–2251)
CL/Fb (L/h/70 kg)
IPV CL
22.1 (12) [34%]3
20.5%
22.7 (18.7–31.2)
24.0 (11.6–69.7)
Residual variability
 Additional error (μg/L) 0.21 (1) 0.21 (0.11–10.5)
 Proportional error 0.39 (19) [7%] 0.33 (0.15–0.46)
 Additional error HPLC–UV 
(μg/L)
26.6 (40) [7%] 25.6 (8.5–39.1)
DBS correction: y = ax + b
 a (μg/L) 0.33 (8) 0.31 (0.19–0.40)
 b (μg/L) 3.90 (15) 3.87 (3.42–14.84)
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3.2.2  Extrapyramidal Symptoms
In four patients, EPS were observed (8% of 50 patients 
with EPS scores). All these four patients came from the 
Dutch sample. For two of these patients, and 44 of the 
patients without EPS, measured trough concentrations 
were available. The median [25th–75th percentile] pipam-
perone trough concentration was lower in patients with 
EPS (25.74 µg/L [8.6–42.9]) than in patients without EPS 
(109.5 µg/L (62.0–174.5). Predicted pipamperone trough 
concentrations (median [25th–75th percentile]) were also 
lower in patients with EPS (46.4 µg/L [22.2–77.1], n = 4) 
than in patients without (99.6 µg/L [57.7–166.8], n = 46), 
p = 0.06. The AUC 24h was significantly lower in patients 
with EPS (1583.0 µg*h/L) than in patients without EPS 
(3633.0 µg*h/L), p = 0.03.
3.2.3  Sedation
Sedation scores were available for 50 patients; nine of whom 
had sedation at least once. For 46 of these patients, meas-
ured trough concentrations were available. The median 
[25th–75th percentile] pipamperone trough concentra-
tion was 77.0 µg/L [36.7–132.5] in patients with sedation 
(n = 6) vs 114.0 µg/L [59.0–174.5] in patients without seda-
tion (n = 40), p = 0.32. The median [25th–75th percentile] 
predicted trough concentration was also non-significantly 
lower in patients with sedation (61.9 µg/L [38.1–88.9], n = 9) 
than patients without sedation (103.8 µg/L [59.9–166.9], 
n = 41), p = 0.08. The AUC 24h was significantly lower in 
patients with sedation than patients without sedation (2050 
vs 3852 µg*h/L, p = 0.02). All patients using benzodiaz-
epines as comedication were not rated as having sedation.
3.2.4  Biochemical Laboratory Parameters
A total of 15 biochemical laboratory measurements were 
available for n = 8 patients (all Dutch patients). The median 
duration (range) of pipamperone use of these patients was 
34  months (1–54). During pipamperone treatment, the 
median (range) prolactin level was 0.3 U/L (0.03–0.46); 
two patients had decreased levels (both did not have prior 
treatment with another antipsychotic), while no patients had 
elevated prolactin levels. The median (range) total choles-
terol level was 4.2 mmol/L (3.5–5.1); no patients had ele-
vated total cholesterol levels. The median (range) triglyc-
eride level was 0.71 mmol/L (0.38–2.06); one patient had 
elevated triglyceride levels (no baseline levels known). Fast-
ing glucose and glycosylated hemoglobin were normal in all 
patients; the median (range) glucose level was 4.7 mmol/L 
(4.2–5.6); the median (range) glycosylated hemoglobin level 
was 32.5 mmol/mol (31–37).
3.3  Predictions
Predicted concentrations with 95% confidence intervals 
using a twice-daily 30-mg dosing scheme in steady state for 
a patient of 25 kg, 50 kg, and 75 kg are shown in Fig. 4a. The 
means (95% confidence intervals) of the predicted pipam-
perone trough concentrations (population prediction) after 
a 30-mg dose were 163.2 (67.3–268.9) µg/L for a patient of 
a
b
Fig. 3  Pipamperone trough concentrations and clinical improvement. 
a Measured trough concentrations vs response based on the Clini-
cal Global Impression Scale. Data available for n = 29 subjects. In 
responders, the measured trough concentration at the time of the first 
response was used. In non-responders, the highest measured trough 
concentration during the follow-up was used. Whiskers indicate 10th–
90th percentiles. b Predicted trough concentrations vs response based 
on the Clinical Global Impression Scale. Data available for n = 35 
subjects. In responders, the predicted trough concentration at the time 
of the first response was used. In non-responders, the highest pre-
dicted trough concentration during the follow-up was used. Whiskers 
indicate 10th–90th percentiles
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25 kg, 103.9 (49.0–167.2) µg/L for a patient of 50 kg, and 
79.3 (38.4–124.4) µg/L for a patient of 75 kg. The same pre-
dictions were performed with a 0.6-mg/kg dosage in a twice-
daily dosing scheme, showing less variability in pipamper-
one concentrations and better attainment of the pipamperone 
trough concentration range that was found to be associated 
with response (Fig. 4b). The means (95% confidence inter-
vals) of the predicted pipamperone trough concentrations 
(population prediction) after a 0.6-mg/kg dosage were 81.6 
(33.6–134.5) µg/L for a patient of 25 kg, 103.9 (49.0–167.2) 
µg/L for a patient of 50 kg, and 119.0 (57.6–186.7) µg/L for 
a patient of 75 kg.
4  Discussion
This is the first study that describes the population pharma-
cokinetics of pipamperone in children and adolescents, and 
investigates the relationships between pipamperone concen-
trations, effectiveness, and side effects in this young popula-
tion. The pediatric pipamperone pharmacokinetics in this 
study are comparable to adult values found in a previously 
published study by Potgieter et al. [21]. This study found 
a mean maximum concentration of 263–266 µg/L after a 
120-mg dose for three pipamperone products in healthy vol-
unteers (mean weight 76.8 kg), corresponding to a calcu-
lated mean volume of distribution of 451–456 L assuming 
a bioavailability of 100%. In our pediatric study sample, 
the mean apparent volume of distribution was estimated at 
416 L/70 kg. Both in our sample and in the study by Potgi-
eter et al., a high variability was found. Strikingly, another 
study performed in adults found relatively low pipamper-
one concentrations after a 40-mg dose, corresponding to a 
more than two-fold larger calculated volume of distribution 
of 908 L [22]. Possibly, the bodyweight of the subjects in 
this latter study was higher, but patient characteristics were 
not provided. It could also be hypothesized that non-linear 
pharmacokinetics underlie these differences; however, this 
was not seen in our sample.
Although well-established reference ranges are lacking 
for pipamperone, the Consensus Guidelines for Therapeutic 
Drug Monitoring in Neuropsychopharmacology recommend 
a therapeutic range between 100 and 400 µg/L for adults 
with psychotic symptoms [40]. In the absence of studies cor-
relating pipamperone concentrations to clinical effects, this 
range is based on expected concentrations at an approved 
dose and derived from the previously mentioned pharma-
cokinetic study by Potgieter et al. [21].
However, ideally, reference ranges are defined by well-
documented concentration–effect relationships in the rel-
evant population [40]. Recently, it has been suggested that 
the Q1–Q3 (25th–75th percentile) range of psychotropic 
drug concentrations in responders would be the most opti-
mal means to define preliminary therapeutic ranges based 
on observationally collected data [41]. In our study, this 
would result in a suggested pipamperone reference range 
for children and adolescents of 56.0–180.5 µg/L. Although 
the indications for use were mostly unknown, it is expected 
that the main indication concerned behavioral problems 
associated with autism spectrum disorders, attention-defi-
cit/hyperactivity disorder, and mental retardation, given the 
major share of these diagnoses in our sample. This range is 
substantially lower than the suggested range in adults, which 
might be partly explained by different indications for use, as 
psychotic symptoms and aggressive behavior are associated 
with different pathomechanisms. However, this needs further 
confirmation for pipamperone. Furthermore, the therapeutic 
reference range for children might be different from the opti-
mal range in adolescents owing to developmental pharma-
codynamic changes, which should be investigated in larger 
prospective trials.
Based on the pipamperone concentration range in 
responders and the population pharmacokinetics within 
our sample, several dose recommendations for children 
and adolescents could be made. First, a twice-daily dosing 
a
b
Fig. 4  Simulations. a Fixed 30-mg dose. Curves represent popula-
tion predictions with 95% confidence intervals using a twice-daily 
pipamperone 30-mg dosing scheme in steady state for a child of 25, 
50, and 75 kg. b 0.6-mg/kg dose. Curves represent population predic-
tions with 95% confidence intervals using a twice-daily pipamperone 
0.6-mg/kg dosing scheme in steady state for a child of 25 kg (15 mg), 
50 kg (30 mg), and 75 kg (45 mg)
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scheme should be sufficient based on the relatively long 
mean elimination half-life (13 h), as has also been found 
for adults (12–30 h) [4, 21]. However, current guidelines 
are not uniform with respect to dosing intervals; while in 
Germany, a dosing interval of three times per day is advised 
[15], the Dutch guideline states one to two times a day [16]. 
Second, a mg/kg dosage seems more appropriate than a fixed 
dosage, as weight was found to significantly influence the 
pharmacokinetics. Based on our simulations, a twice-daily 
0.6-mg/kg dosage seems appropriate to attain the concen-
tration range that was associated with response. However, 
given the large variability between patients, some patients 
might have adequate response with lower dosages, while 
others need higher dosages. This calls for careful pipamper-
one dosage titration.
Strikingly, children and adolescents with side effects had 
lower pipamperone concentrations than subjects without side 
effects in our study. This is remarkable, as previous studies 
have found that a higher  D2 receptor occupancy, as a result 
of higher antipsychotic concentrations, is associated with 
an increased risk for EPS [42]. Certain children and adoles-
cents might be more susceptible to side effects based on their 
pharmacodynamic profile, which makes them prone to side 
effects even at low pipamperone concentrations, preventing 
a further dosage increase. It might be hypothesized that this 
is the case for younger children, who have been found to 
be more vulnerable for other side effects associated with 
antipsychotic use as well [43]. However, patients with EPS 
were not generally younger than patients in our sample; nei-
ther did patients with EPS have other psychopathology than 
generally in the sample. Possibly, certain genetic variances 
underlie the elevated risk, as certain polymorphisms in the 
dopamine and serotonin receptors have been suggested to be 
risk factors for antipsychotic-induced side effects in adults 
[44]. Another explanation is that part of the side effects may 
be due to the nocebo effect, as with off-label use patients 
and legal representatives are informed about potential effects 
and side effects in a very detailed manner. However, it is 
more likely that side effects have been over-estimated in the 
Dutch patients, while underestimated in the German patients 
in our study. While the Dutch patients were enrolled in a 
clinical trial with structured screening and reporting of side 
effects, it is expected that in the daily practice of the German 
TDM service relatively less side effects were reported. As 
the pipamperone dosages and concentrations were higher in 
the German sample, this might have led to the finding that 
higher concentrations are associated with fewer side effects.
In this study, the DBS method was used as pharmacoki-
netic sampling method next to conventional venipuncture. 
The DBS method only involves one finger prick for a drug 
concentration measurement and can be performed in the 
home setting, which makes it a promising less invasive 
method for pharmacokinetic sampling in children. The 
development of a DBS assay requires a thorough validation 
process before implementation, including the assessment 
of agreement between DBS samples and simultaneously 
collected plasma samples in a real-life clinical setting [45]. 
During this previously performed clinical validation study 
for pipamperone, the best agreement was found by dividing 
DBS samples by 0.158 (corresponding to a recovery of ca 
16% in DBS) [28]. However, in our model, this conversion 
of the DBS samples initially led to a clear underestimation of 
the predicted plasma concentrations. This proportional bias 
was resolved by a new conversion of DBS concentrations 
to estimated plasma concentrations, being estimated by the 
model: DBS/0.33 + 3.90 (see Table 2). However, this finding 
questions the validity of the clinical validation process in our 
pediatric population. After consultation with the medical 
ethics committee, the clinical validation was performed in 
adults because of ethical concerns.
However, several factors may differentially impact DBS 
recovery of pipamperone in children vs adults. This could 
include the amount of interstitial fluid that is collected dur-
ing the finger prick, which may be more in adults. Further-
more, sampling in children may require more pressure on the 
finger to collect a full blood spot, and this may have caused 
hemolysis. Our findings show that results cannot simply be 
generalized across age groups and performing a clinical vali-
dation study in the intended target group should hence be 
considered. At the same time, in the clinical validation study, 
a suboptimal agreement was already observed, which was 
confirmed by the findings in our population.
The results of this study must be considered in the con-
text of its limitations. The pipamperone concentrations were 
collected in an observational setting with flexible dosing 
schemes in clinical practice. As has been suggested earlier, 
this study design is suboptimal to demonstrate concentra-
tion–effect relationships [41, 46]. Placebo responders, who 
generally represent a substantial share of the patients in 
psychiatry, are likely to receive lower dosages, while non-
responders might receive higher dosages. Additionally, 
dosages might be lowered when side effects are observed. 
Therefore, the observed relationships between clinical 
effects and pipamperone concentrations could be biased. 
Furthermore, the analyses were performed with two differ-
ent datasets. The data were collected in two countries, with 
different clinical and laboratory assessment methods, differ-
ent inclusion criteria, and prospectively vs retrospectively 
collected data. The data in Dutch patients were collected by 
a screening-based method, with questionnaires and screen-
ing tools being applied at fixed time points, while in German 
patients, improvement was retrospectively scored and side 
effects were only reported at the time of sampling. Possibly, 
this might have led to an overestimation of side effects in 
the Dutch patients and an underestimation in the German 
patients.
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As the pharmacodynamic data on response were mainly 
retrospectively scored and collected in patients with various 
indications for use, these data did not allow for a more exten-
sive exposure–response analysis. Despite combining the two 
datasets, the total number of patients was relatively low, 
and the relatively sparse amount of non-trough pipamper-
one concentrations might have limited the pharmacokinetic 
model development. As pipamperone is relatively lipophilic, 
it is expected to distribute to peripheral tissues. However, 
our data were possibly too sparse to support a two-compart-
ment model, although a one-compartment model reflected 
the observed data best. Furthermore, different matrices and 
analytical methods were used to determine pipamperone 
concentrations, further increasing variability despite the cor-
rections within the error model for these influences. Last, the 
influence of metabolizing enzymes such as cytochrome P450 
could not be tested. Although the metabolism of pipamper-
one is assumed to take place in the liver, it is unknown which 
cytochrome P450 enzyme(s) are involved [40].
5  Conclusions
This study presents the pharmacokinetics and pharmacody-
namics of pipamperone in children and adolescents, based 
on concentrations measured in a real-life clinical setting. 
Based on our findings, we recommend a twice-daily dosing 
scheme for pipamperone in this population. Furthermore, 
bodyweight should be taken into account when dosing 
pipamperone in children and adolescents. Although more 
research is needed for the routine application of TDM in 
children and adolescents, we suggest considerably lower 
reference ranges than suggested for adults.
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